Cullinan Therapeutics, Inc. (CGEM) income statement
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.01−0.27 (-2.86%)
Close on Nov 18, 2026Market cap $579.84MP/E –Yield –
Cullinan Therapeutics, Inc. financial ratios
See a number that looks wrong?